CytomX Therapeutics (CTMX) Operating Expenses (2014 - 2026)

CytomX Therapeutics has reported Operating Expenses for 13 years, with the latest figure at $29.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 5.77% year-over-year to $29.9 million; the trailing twelve-month figure through Mar 2026 stood at $100.2 million (down 10.21% YoY), and the FY2025 full-year result was $98.6 million, down 12.86% from the prior year.
• Operating Expenses for Q1 2026 stood at $29.9 million, up from $28.6 million in the prior quarter.
• The five-year high for Operating Expenses was $42.9 million in Q2 2022, with the low at $19.9 million in Q2 2025.
• Historically, Operating Expenses has averaged $29.6 million across 5 years, with a median of $29.2 million in 2023.
• Annual changes were most pronounced in 2023 — Operating Expenses tumbled 43.07% — and 2025, when it surged 40.08%.
• CytomX Therapeutics' Operating Expenses stood at $29.6 million in 2022, then retreated by 8.16% to $27.2 million in 2023, then retreated by 24.98% to $20.4 million in 2024, then soared by 40.08% to $28.6 million in 2025, then increased by 4.67% to $29.9 million in 2026.
• The last three Operating Expenses figures came in at $29.9 million (Q1 2026), $28.6 million (Q4 2025), and $21.7 million (Q3 2025), per Business Quant data.